FARHAD JAMALI: Open Payments
NPI 1548248388 · GLENN DALE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,665 in 129 payments from 26 companies in 2025. Trend: 2023 $3,044 · 2024 $2,219 · 2025 $2,665
Food & beverage: $2,665
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $319 |
| Corcept Therapeutics | 12 | $313 |
| PFIZER INC. | 12 | $233 |
| Lilly USA, LLC | 11 | $210 |
| GlaxoSmithKline, LLC. | 9 | $195 |
| ABBVIE INC. | 8 | $181 |
| Lundbeck LLC | 10 | $179 |
| Amgen Inc. | 11 | $141 |
| AstraZeneca Pharmaceuticals LP | 6 | $138 |
| Exact Sciences Corporation | 5 | $107 |
Products named: Korlym, TRELEGY ELLIPTA, NURTEC ODT, REXULTI, MOUNJARO, Ozempic, Cologuard Collection Kit, Wegovy.
Industry payments across MD — which companies pay providers there.
